抗凝固の世界市場

出版：Market Research Future（マーケットリサーチフューチャー）　出版年月：2021年8月

抗凝固の世界市場:薬剤分類別の情報[新規、直接抗凝固薬(DOAC）、ヘパリン、低分子量（LMWH）、ワルファリン、ビタミンK拮抗薬]、疾患の兆候[心房細動（A-Fib）、脳卒中、深部静脈血栓症/肺塞栓症（PE）、メカニカルハートバルブ（MHV）]、投与経路（経口、注射）、流通経路（病院薬局、小売薬局、オンライン薬局）、地域（北米、ヨーロッパ、アジア太平洋、その他の地域） – 2027年までの予測

Global Anticoagulation Market: Information by Drug Class (Novel and Direct Anticoagulants [DOACs], Heparin and Low Molecular Weight [LMWH], Warfarin, Vitamin K Antagonists), Disease Indication(Anti Fibrillation [A-Fib], Stroke, Deep Vein Thrombosis/Pulmonary Embolism [PE], Mechanical Heart Valves [MHV]), Route of Administration (Oral and Injectable), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Region (North America, Europe, Asia-Pacific, and Rest of the World)—Forecast till 2027

–

このレポートへお問合せ　　レポート目次

–

Global Anticoagulation Market—Forecast till 2027

Anticoagulation Market Snapshot

As per the Market research future analysis, the global anticoagulation market is anticipated to register a CAGR of 7.80% during the review period to surpass USD 31,696.59 million by 2027. Anticoagulants are ordinarily known as blood thinners, which are compound substances that decrease blood coagulation and blood thickening time. Oral anticoagulants are accessible in different measurements structures, for example, pill or tablet structure and intravenous dose. Moreover, a portion of the anticoagulants is utilized in clinical hardware, for example, test tubes, blood bonding sacks, and dialysis gear. In addition, warfarin was initially supported as an anticoagulant.
The growth of the global anticoagulation market is attributed to the increasing prevalence of cardiovascular and coronary artery diseases, dependence on anticoagulants, and the growing geriatric population. Many major market players and entrants have various attractive market opportunities due to the growing patient population supporting new product launches. However, stringent regulatory policies are expected to hinder market growth during the review period.
Segment Overview
The global anticoagulation market has been classified into Direct Oral Anticoagulants (DOACS), Disease Indication, Route of Administration (ROA), a distribution channel.
The direct oral anticoagulants segment has been further classified into Warfarin, other vitamin K, and Low Molecular Weight Heparin (LMWH).
Based on Disease Indication the global market is divided into
Heart Attack, Stroke, Deep Vein Thrombosis/ Pulmonary Embolism DVT/PE, Mechanical Heart Valves (MHV).

Based on the Route of Administration (ROA) segment the global market has been segmented into Oral, injectable, and others.
By Distribution Channel the global market has been classified into Retail Pharmacy, Hospital Pharmacies, and Online Pharmacies.

Regional Analysis

North America is likely to hold the greatest piece of the pie during the review time frame. In North America, the anticoagulation market is driven by an expanding number of heart patients, rising mindfulness about constant and way of life infections, new item dispatches, and the presence of major players. Since medical care consumption is high in North America, anticoagulation is broadly used to lessen cluster arrangement, prompting the danger of coronary illness.

Asia-Pacific is expected to enroll the most elevated development rate during the figure time frame from 2020 to 2027. This is because of variables such as an expanding predominance of constant illness, enormous populace base, ascent in geriatric populace, rising discretionary cash flow, and increasing fabricating offices of vital participants.
Europe represented a market size of USD 5,205.37million in 2019 and is relied upon to show a CAGR of 7.26%during the gauge time frame. The market development is licensed to the ascent in research & development activities, expanded commonness of ongoing heart sicknesses, and an ascent sought after for cutting edge therapeutics.

Major Companies Covered

The key players of the global anticoagulation market are Pfizer Inc (US), Novartis AG (Switzerland), Sanofi (France), GlaxoSmithKline plc (UK), Daiichi Sankyo Company, Limited (Japan), Johnson & Johnson Services Inc (US), Boehringer Ingelheim International GmbH (Germany), Bristol-Myers Squibb Company (US), Hoffmann-La Roche Ltd (Switzerland), and Portola Pharmaceuticals, Inc (US).

COVID 19 Impacts
We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.

目次

LIST OF CONTENTS

1 EXECUTIVE SUMMARY 14

2 MARKET INTRODUCTION 15

2.1 DEFINITION 15

2.2 SCOPE OF THE STUDY 15

2.3 RESEARCH OBJECTIVE 15

2.4 MARKET STRUCTURE 15

2.5 ASSUMPTIONS & LIMITATIONS 16

3 RESEARCH METHODOLOGY 17

3.1 DATA MINING 17

3.2 SECONDARY RESEARCH 18

3.3 PRIMARY RESEARCH 18

3.4 BREAKDOWN OF PRIMARY RESPONDENTS 19

3.5 FORECASTING TECHNIQUES 20

3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 21

3.6.1 BOTTOM-UP APPROACH 22

3.6.2 TOP-DOWN APPROACH 22

3.7 DATA TRIANGULATION 23

3.8 VALIDATION 23

4 MARKET DYNAMICS 24

4.1 OVERVIEW 24

4.2 DRIVERS 25

4.2.1 RISING INCIDENCE OF CARDIOVASCULAR AND CORONARY ARTERY DISEASES 25

4.2.2 GROWING AWARENESS, EXPENDITURE, AND DEPENDENCE ON ANTICOAGULANTS 25

4.3 RESTRAINTS 26

4.3.1 STRINGENT REGULATORY NORMS 26

4.4 OPPORTUNITIES 27

4.4.1 INCREASING PATIENT POPULATION AND PATENT EXPIRY TO SUPPORT NEW PRODUCT LAUNCH 27

5 MARKET FACTOR ANALYSIS 28

5.1 VALUE CHAIN ANALYSIS 28

5.1.1 R&D 29

5.1.2 MANUFACTURING 29

5.1.3 DISTRIBUTION AND SALES 29

5.1.4 POST-SALES MONITORING 29

5.2 PORTER’S FIVE FORCES MODEL 29

5.2.1 BARGAINING POWER OF SUPPLIERS 30

5.2.2 BARGAINING POWER OF BUYERS 30

5.2.3 THREAT OF NEW ENTRANTS 30

5.2.4 THREAT OF SUBSTITUTES 31

5.2.5 INTENSITY OF RIVALRY 31

5.2.6 US AND GLOBAL NUMBER OF PATIENTS ON ANTICOAGULANTS (2019), IN MILLION 31

5.3 IMPACT OF COVID-19 ON THE ANTICOAGULATION MARKET 32

5.3.1 OVERVIEW 32

5.3.2 IMPACT ON SUPPLY CHAIN 32

5.3.3 IMPACT ON DEMAND FOR ANTICOAGULATION DRUGS 32

5.3.4 EFFECT 0F ANTICOAGULATION ON COVID-19 PATIENTS 33

5.4 PATENT EXPIRATION OF ALL KEY DOACS 34

5.4.1 INTRODUCTION 34

6 GLOBAL ANTICOAGULATION MARKET, BY DRUG CLASS 35

6.1 OVERVIEW 35

6.2 DOACS 36

6.3 WARFARIN 38

6.4 OTHER VITAMIN K 39

6.5 LMWH 40

7 GLOBAL ANTICOAGULATION MARKET, BY DISEASE INDICATION 41

7.1 OVERVIEW 41

7.2 HEART ATTACK 42

7.3 STROKE 42

7.4 DVT/PE 43

7.5 MHV 43

7.6 OTHERS 44

8 GLOBAL ANTICOAGULATION MARKET, BY ROA 45

8.1 OVERVIEW 45

8.2 ORAL 46

8.3 INJECTABLE 46

8.4 OTHERS 47

9 GLOBAL ANTICOAGULATION MARKET, BY DISTRIBUTION CHANNEL 48

9.1 OVERVIEW 48

9.2 RETAIL PHARMACY 49

9.3 HOSPITAL PHARMACIES 49

9.4 ONLINE PHARMACIES 50

10 GLOBAL ANTICOAGULATION MARKET, BY REGION 51

10.1 OVERVIEW 51

10.2 NORTH AMERICA 53

10.2.1 US 55

10.2.2 CANADA 57

10.3 EUROPE 59

10.3.1 GERMANY 61

10.3.2 UK 63

10.3.3 FRANCE 65

10.3.4 ITALY 67

10.3.5 SPAIN 69

10.3.6 REST OF EUROPE 71

10.4 ASIA-PACIFIC 73

10.5 REST OF THE WORLD 86

11 COMPETITIVE LANDSCAPE 94

11.1 OVERVIEW 94

11.2 COMPETITIVE BENCHMARKING 95

11.3 GLOBAL ANTICOAGULATION MARKET: COMPANY RANKING 96

11.4 LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS 97

11.5 KEY DEVELOPMENTS & GROWTH STRATEGIES 97

11.5.1 NEW PRODUCT LAUNCHES 97

11.6 FINANCIAL MATRIX 98

12 COMPANY PROFILES 99

12.1 PFIZER, INC. 99

12.1.1 COMPANY OVERVIEW 99

12.1.2 FINANCIAL OVERVIEW 100

12.1.3 PRODUCTS/SERVICES OFFERED 100

12.1.4 KEY DEVELOPMENTS 100

12.1.5 SWOT ANALYSIS 101

12.1.6 KEY STRATEGIES 101

12.2 SANOFI 102

12.2.1 COMPANY OVERVIEW 102

12.2.2 FINANCIAL OVERVIEW 102

12.2.3 PRODUCTS/SERVICES OFFERED 103

12.2.4 KEY DEVELOPMENTS 103

12.2.5 SWOT ANALYSIS 103

12.2.6 KEY STRATEGIES 103

12.3 JOHNSON & JOHNSON SERVICES INC. 104

12.3.1 COMPANY OVERVIEW 104

12.3.2 FINANCIAL OVERVIEW 104

12.3.3 PRODUCTS/SERVICES OFFERED 105

12.3.4 KEY DEVELOPMENTS 105

12.3.5 SWOT ANALYSIS 105

12.3.6 KEY STRATEGIES 105

12.4 GLAXOSMITHKLINE PLC 106

12.4.1 COMPANY OVERVIEW 106

12.4.2 FINANCIAL OVERVIEW 106

12.4.3 PRODUCTS/SERVICES OFFERED 107

12.4.4 KEY DEVELOPMENTS 107

12.4.5 SWOT ANALYSIS 107

12.4.6 KEY STRATEGIES 107

12.5 DAIICHI SANKYO COMPANY, LIMITED 108

12.5.1 COMPANY OVERVIEWS 108

12.5.2 FINANCIAL OVERVIEW 108

12.5.3 PRODUCTS/SERVICES OFFERED 109

12.5.4 KEY DEVELOPMENTS 109

12.5.5 SWOT ANALYSIS 109

12.5.6 KEY STRATEGIES 110

12.6 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 111

12.6.1 COMPANY OVERVIEW 111

12.6.2 FINANCIAL OVERVIEW 112

12.6.3 PRODUCTS/SERVICES OFFERED 112

12.6.4 KEY DEVELOPMENTS 113

12.6.5 SWOT ANALYSIS 113

12.6.6 KEY STRATEGIES 113

12.7 BRISTOL-MYERS SQUIBB COMPANY 114

12.7.1 COMPANY OVERVIEW 114

12.7.2 FINANCIAL OVERVIEW 114

12.7.3 PRODUCTS/SERVICES OFFERED 115

12.7.4 KEY DEVELOPMENTS 115

12.7.5 SWOT ANALYSIS 115

12.7.6 KEY STRATEGIES 115

12.8 PORTOLA PHARMACEUTICALS, INC 116

12.8.1 COMPANY OVERVIEW 116

12.8.2 FINANCIAL OVERVIEW 116

12.8.3 PRODUCTS/SERVICES OFFERED 117

12.8.4 KEY DEVELOPMENTS 117

12.8.5 SWOT ANALYSIS 118

12.8.6 KEY STRATEGIES 118

12.9 NOVARTIS AG 119

12.9.1 COMPANY OVERVIEW 119

12.9.2 FINANCIAL OVERVIEW 119

12.9.3 PRODUCTS/SERVICES OFFERED 120

12.9.4 KEY DEVELOPMENTS 120

12.9.5 SWOT ANALYSIS 120

12.9.6 KEY STRATEGIES 120

12.10 F. HOFFMANN-LA ROCHE LTD 121

12.10.1 COMPANY OVERVIEW 121

12.10.2 FINANCIAL OVERVIEW 122

12.10.3 PRODUCTS/SERVICES OFFERED 122

12.10.4 KEY DEVELOPMENTS 122

12.10.5 SWOT ANALYSIS 123

12.10.6 KEY STRATEGIES 123

13 APPENDIX 124

13.1 REFERENCES 124

13.2 RELATED REPORTS 124

LIST OF TABLES

TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS 16

TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 19

TABLE 3 LIST OF KEY DOACS AND THEIR PATENT EXPIRATION 34

TABLE 4 GLOBAL: ANTICOAGULATION MARKET, BY DRUG CLASS, 2017–2027 (USD MILLION) 35

TABLE 5 GLOBAL: ANTICOAGULATION MARKET, BY DOACS, 2017–2027 (USD MILLION), BY REGION, 2017–2027 (USD MILLION) 36

TABLE 6 GLOBAL: ANTICOAGULATION MARKET, FOR DOACS, BY TYPE, 2017–2027 (USD MILLION), BY REGION, 2017–2027 (USD MILLION) 36

TABLE 7 GLOBAL: ANTICOAGULATION MARKET, FOR APIXABAN,BY DOACS 2017–2027 (USD MILLION), BY REGION, 2017–2027 (USD MILLION) 37

TABLE 8 GLOBAL: ANTICOAGULATION MARKET, FOR RIVAROXABAN,BY DOACS 2017–2027 (USD MILLION), BY REGION, 2017–2027 (USD MILLION) 37

TABLE 9 GLOBAL: ANTICOAGULATION MARKET, FOR EDOXABAN,BY DOACS 2017–2027 (USD MILLION), BY REGION, 2017–2027 (USD MILLION) 37

TABLE 10 GLOBAL: ANTICOAGULATION MARKET, FOR DABIGATRAN,BY DOACS 2017–2027 (USD MILLION), BY REGION, 2017–2027 (USD MILLION) 38

TABLE 11 GLOBAL: ANTICOAGULATION MARKET, FOR BETRIXABAN,BY DOACS 2017–2027 (USD MILLION), BY REGION, 2017–2027 (USD MILLION) 38

TABLE 12 GLOBAL: ANTICOAGULATION MARKET, FOR WARFARIN BY DRUG CLASS, 2017–2027 (USD MILLION), BY REGION, 2017–2027 (USD MILLION) 39

TABLE 13 GLOBAL: ANTICOAGULATION MARKET, OTHER VITAMIN K, BY DRUG CLASS 2017–2027 (USD MILLION), BY REGION, 2017–2027 (USD MILLION) 39

TABLE 14 GLOBAL: ANTICOAGULATION MARKET, BY OTHER VITAMIN K, 2017–2027 (USD MILLION), BY REGION, 2017–2027 (USD MILLION) 40

TABLE 15 GLOBAL: ANTICOAGULATION MARKET, BY DISEASE INDICATION, 2017–2027 (USD MILLION) 41

TABLE 16 GLOBAL: ANTICOAGULATION MARKET, FOR HEART ATTACK BY DISEASE INDICATION, 2017–2027 (USD MILLION), BY REGION, 2017–2027 (USD MILLION) 42

TABLE 17 GLOBAL: ANTICOAGULATION MARKET, FOR STROKEBY DISEASE INDICATION, 2017–2027 (USD MILLION), BY REGION, 2017–2027 (USD MILLION) 42

TABLE 18 GLOBAL: ANTICOAGULATION MARKET, FOR DVT/PEBY DISEASE INDICATION, 2017–2027 (USD MILLION), BY REGION, 2017–2027 (USD MILLION) 43

TABLE 19 GLOBAL: ANTICOAGULATION MARKET, FOR DVT/PEBY DISEASE INDICATION, 2017–2027 (USD MILLION), BY REGION, 2017–2027 (USD MILLION) 43

TABLE 20 GLOBAL: ANTICOAGULATION MARKET, FOR OTHERSBY DISEASE INDICATION, 2017–2027 (USD MILLION), BY REGION, 2017–2027 (USD MILLION) 44

TABLE 21 GLOBAL: ANTICOAGULATION MARKET, BY ROA, 2017–2027 (USD MILLION) 45

TABLE 22 GLOBAL: ANTICOAGULATION MARKET, FOR ORAL BY ROA, 2017–2027 (USD MILLION), BY REGION, 2017–2027 (USD MILLION) 46

TABLE 23 GLOBAL: ANTICOAGULATION MARKET, FOR INJECTABLEBY ROA, 2017–2027 (USD MILLION), BY REGION, 2017–2027 (USD MILLION) 46

TABLE 24 GLOBAL: ANTICOAGULATION MARKET, FOR OTHERSBY ROA, 2017–2027 (USD MILLION), BY REGION, 2017–2027 (USD MILLION) 47

TABLE 25 GLOBAL: ANTICOAGULATION MARKET, BY DISTRIBUTION CHANNEL, 2017–2027 (USD MILLION) 48

TABLE 26 GLOBAL: ANTICOAGULATION MARKET, FOR RETAIL PHARMACYBY DISTRIBUTION CHANNEL, 2017–2027 (USD MILLION), BY REGION, 2017–2027 (USD MILLION) 49

TABLE 27 GLOBAL: ANTICOAGULATION MARKET, FOR MEDICAL STOREBY DISTRIBUTION CHANNEL, 2017–2027 (USD MILLION), BY REGION, 2017–2027 (USD MILLION) 49

TABLE 28 GLOBAL: ANTICOAGULATION MARKET, FOR ONLINE PHARMACIESBY DISTRIBUTION CHANNEL, 2017–2027 (USD MILLION), BY REGION, 2017–2027 (USD MILLION) 50

TABLE 29 GLOBAL: ANTICOAGULATION MARKET, BY REGION, 2017–2027 (USD MILLION) 51

TABLE 30 NORTH AMERICA: ANTICOAGULATION MARKET, BY COUNTRY, 2017–2027 (USD MILLION) 53

TABLE 31 NORTH AMERICA: ANTICOAGULATION MARKET, BY DRUG CLASS, 2017–2027 (USD MILLION) 54

TABLE 32 NORTH AMERICA: ANTICOAGULATION MARKET, BY DOACS, 2017–2027 (USD MILLION) 54

TABLE 33 NORTH AMERICA: ANTICOAGULATION MARKET, BY DISEASE INDICATION, 2017–2027 (USD MILLION) 54

TABLE 34 NORTH AMERICA: ANTICOAGULATION MARKET, BY ROA, 2017–2027 (USD MILLION) 55

TABLE 35 NORTH AMERICA: ANTICOAGULATION MARKET, BY DISTRIBUTION CHANNEL, 2017–2027 (USD MILLION) 55

TABLE 36 US ANTICOAGULATION MARKET, BY DRUG CLASS, 2017–2027 (USD MILLION) 55

TABLE 37 US: ANTICOAGULATION MARKET, BY DOACS, 2017–2027 (USD MILLION) 56

TABLE 38 US: ANTICOAGULATION MARKET, BY DISEASE INDICATION, 2017–2027 (USD MILLION) 56

TABLE 39 US: ANTICOAGULATION MARKET, BY ROA, 2017–2027 (USD MILLION) 56

TABLE 40 US: ANTICOAGULATION MARKET, BY DISTRIBUTION CHANNEL, 2017–2027 (USD MILLION) 57

TABLE 41 CANADA ANTICOAGULATION MARKET, BY DRUG CLASS, 2017–2027 (USD MILLION) 57

TABLE 42 CANADA: ANTICOAGULATION MARKET, BY DOACS, 2017–2027 (USD MILLION) 57

TABLE 43 CANADA: ANTICOAGULATION MARKET, BY DISEASE INDICATION, 2017–2027 (USD MILLION) 58

TABLE 44 CANADA: ANTICOAGULATION MARKET, BY ROA, 2017–2027 (USD MILLION) 58

TABLE 45 CANADA: ANTICOAGULATION MARKET, BY DISTRIBUTION CHANNEL, 2017–2027 (USD MILLION) 58

TABLE 46 EUROPE: ANTICOAGULATION MARKET, BY COUNTRY, 2017–2027 (USD MILLION) 59

TABLE 47 EUROPE: ANTICOAGULATION MARKET, BY DRUG CLASS, 2017–2027 (USD MILLION) 60

TABLE 48 EUROPE: ANTICOAGULATION MARKET, BY DOACS, 2017–2027 (USD MILLION) 60

TABLE 49 EUROPE: ANTICOAGULATION MARKET, BY DISEASE INDICATION, 2017–2027 (USD MILLION) 60

TABLE 50 EUROPE: ANTICOAGULATION MARKET, BY ROA, 2017–2027 (USD MILLION) 61

TABLE 51 EUROPE: ANTICOAGULATION MARKET, BY DISTRIBUTION CHANNEL, 2017–2027 (USD MILLION) 61

TABLE 52 GERMANY: ANTICOAGULATION MARKET, BY DRUG CLASS, 2017–2027 (USD MILLION) 61

TABLE 53 GERMANY: ANTICOAGULATION MARKET, BY DOACS, 2017–2027 (USD MILLION) 62

TABLE 54 GERMANY: ANTICOAGULATION MARKET, BY DISEASE INDICATION, 2017–2027 (USD MILLION) 62

TABLE 55 GERMANY: ANTICOAGULATION MARKET, BY ROA, 2017–2027 (USD MILLION) 62

TABLE 56 GERMANY: ANTICOAGULATION MARKET, BY DISTRIBUTION CHANNEL, 2017–2027 (USD MILLION) 63

TABLE 57 UK: ANTICOAGULATION MARKET, BY DRUG CLASS, 2017–2027 (USD MILLION) 63

TABLE 58 UK: ANTICOAGULATION MARKET, BY DIRECT ORAL ANTICOAGULANTS (DOACS), 2017–2027 (USD MILLION) 63

TABLE 59 UK: ANTICOAGULATION MARKET, BY DISEASE INDICATION, 2017–2027 (USD MILLION) 64

TABLE 60 UK: ANTICOAGULATION MARKET, BY ROA, 2017–2027 (USD MILLION) 64

TABLE 61 UK: ANTICOAGULATION MARKET, BY DISTRIBUTION CHANNEL, 2017–2027 (USD MILLION) 64

TABLE 62 FRANCE: ANTICOAGULATION MARKET, BY DRUG CLASS, 2017–2027 (USD MILLION) 65

TABLE 63 FRANCE: ANTICOAGULATION MARKET, BY DIRECT ORAL ANTICOAGULANTS (DOACS), 2017–2027 (USD MILLION) 65

TABLE 64 FRANCE: ANTICOAGULATION MARKET, BY DISEASE INDICATION, 2017–2027 (USD MILLION) 66

TABLE 65 FRANCE: ANTICOAGULATION MARKET, BY ROA, 2017–2027 (USD MILLION) 66

TABLE 66 FRANCE: ANTICOAGULATION MARKET, BY DISTRIBUTION CHANNEL, 2017–2027 (USD MILLION) 66

TABLE 67 ITALY: ANTICOAGULATION MARKET, BY DRUG CLASS, 2017–2027 (USD MILLION) 67

TABLE 68 ITALY: ANTICOAGULATION MARKET, BY DIRECT ORAL ANTICOAGULANTS (DOACS), 2017–2027 (USD MILLION) 67

TABLE 69 ITALY: ANTICOAGULATION MARKET, BY DISEASE INDICATION, 2017–2027 (USD MILLION) 68

TABLE 70 ITALY: ANTICOAGULATION MARKET, BY ROA, 2017–2027 (USD MILLION) 68

TABLE 71 ITALY: ANTICOAGULATION MARKET, BY DISTRIBUTION CHANNEL, 2017–2027 (USD MILLION) 68

TABLE 72 SPAIN: ANTICOAGULATION MARKET, BY DRUG CLASS, 2017–2027 (USD MILLION) 69

TABLE 73 SPAIN: ANTICOAGULATION MARKET, BY DIRECT ORAL ANTICOAGULANTS (DOACS), 2017–2027 (USD MILLION) 69

TABLE 74 SPAIN: ANTICOAGULATION MARKET, BY DISEASE INDICATION, 2017–2027 (USD MILLION) 70

TABLE 75 SPAIN: ANTICOAGULATION MARKET, BY ROA, 2017–2027 (USD MILLION) 70

TABLE 76 SPAIN: ANTICOAGULATION MARKET, BY DISTRIBUTION CHANNEL, 2017–2027 (USD MILLION) 70

TABLE 77 REST OF EUROPE: ANTICOAGULATION MARKET, BY DIRECT ORAL ANTICOAGULANTS (DOACS), 2017–2027 (USD MILLION) 71

TABLE 78 REST OF EUROPE: ANTICOAGULATION MARKET, BY DISEASE INDICATION, 2017–2027 (USD MILLION) 71

TABLE 79 REST OF EUROPE: ANTICOAGULATION MARKET, BY ROA, 2017–2027 (USD MILLION) 72

TABLE 80 REST OF EUROPE: ANTICOAGULATION MARKET, BY DISTRIBUTION CHANNEL, 2017–2027 (USD MILLION) 72

TABLE 81 ASIA-PACIFIC: ANTICOAGULATION MARKET, BY COUNTRY, 2017–2027 (USD MILLION) 73

TABLE 82 ASIA-PACIFIC: ANTICOAGULATION MARKET SHARE, BY COUNTRY 2019 (%) 73

TABLE 83 ASIA-PACIFIC: ANTICOAGULATION MARKET, BY DRUG CLASS, 2017–2027 (USD MILLION) 74

TABLE 84 ASIA-PACIFIC: ANTICOAGULATION MARKET, BY DIRECT ORAL ANTICOAGULANTS (DOACS), 2017–2027 (USD MILLION) 74

TABLE 85 ASIA-PACIFIC: ANTICOAGULATION MARKET, BY DISEASE INDICATION, 2017–2027 (USD MILLION) 74

TABLE 86 ASIA-PACIFIC: ANTICOAGULATION MARKET, BY ROA, 2017–2027 (USD MILLION) 75

TABLE 87 ASIA-PACIFIC: ANTICOAGULATION MARKET, BY DISTRIBUTION CHANNEL, 2017–2027 (USD MILLION) 75

TABLE 88 CHINA: ANTICOAGULATION MARKET, BY DRUG CLASS, 2017–2027 (USD MILLION) 75

TABLE 89 CHINA: ANTICOAGULATION MARKET, BY DIRECT ORAL ANTICOAGULANTS (DOACS), 2017–2027 (USD MILLION) 76

TABLE 90 CHINA: ANTICOAGULATION MARKET, BY DISEASE INDICATION, 2017–2027 (USD MILLION) 76

TABLE 91 CHINA: ANTICOAGULATION MARKET, BY ROA, 2017–2027 (USD MILLION) 76

TABLE 92 CHINA: ANTICOAGULATION MARKET, BY DISTRIBUTION CHANNEL, 2017–2027 (USD MILLION) 77

TABLE 93 INDIA: ANTICOAGULATION MARKET, BY DRUG CLASS, 2017–2027 (USD MILLION) 77

TABLE 94 INDIA: ANTICOAGULATION MARKET, BY DIRECT ORAL ANTICOAGULANTS (DOACS), 2017–2027 (USD MILLION) 77

TABLE 95 INDIA: ANTICOAGULATION MARKET, BY DISEASE INDICATION, 2017–2027 (USD MILLION) 78

TABLE 96 INDIA: ANTICOAGULATION MARKET, BY ROA, 2017–2027 (USD MILLION) 78

TABLE 97 INDIA: ANTICOAGULATION MARKET, BY DISTRIBUTION CHANNEL, 2017–2027 (USD MILLION) 78

TABLE 98 JAPAN: ANTICOAGULATION MARKET, BY DRUG CLASS, 2017–2027 (USD MILLION) 79

TABLE 99 JAPAN: ANTICOAGULATION MARKET, BY DIRECT ORAL ANTICOAGULANTS (DOACS), 2017–2027 (USD MILLION) 79

TABLE 100 JAPAN: ANTICOAGULATION MARKET, BY DISEASE INDICATION, 2017–2027 (USD MILLION) 79

TABLE 101 JAPAN: ANTICOAGULATION MARKET, BY ROA, 2017–2027 (USD MILLION) 80

TABLE 102 JAPAN: ANTICOAGULATION MARKET, BY DISTRIBUTION CHANNEL, 2017–2027 (USD MILLION) 80

TABLE 103 AUSTRALIA: ANTICOAGULATION MARKET, BY DRUG CLASS, 2017–2027 (USD MILLION) 80

TABLE 104 AUSTRALIA: ANTICOAGULATION MARKET, BY DIRECT ORAL ANTICOAGULANTS (DOACS), 2017–2027 (USD MILLION) 81

TABLE 105 AUSTRALIA: ANTICOAGULATION MARKET, BY DISEASE INDICATION, 2017–2027 (USD MILLION) 81

TABLE 106 AUSTRALIA: ANTICOAGULATION MARKET, BY ROA, 2017–2027 (USD MILLION) 81

TABLE 107 AUSTRALIA: ANTICOAGULATION MARKET, BY DISTRIBUTION CHANNEL, 2017–2027 (USD MILLION) 82

TABLE 108 SOUTH KOREA: ANTICOAGULATION MARKET, BY DRUG CLASS, 2017–2027 (USD MILLION) 82

TABLE 109 SOUTH KOREA: ANTICOAGULATION MARKET, BY DIRECT ORAL ANTICOAGULANTS (DOACS), 2017–2027 (USD MILLION) 82

TABLE 110 SOUTH KOREA: ANTICOAGULATION MARKET, BY DISEASE INDICATION, 2017–2027 (USD MILLION) 83

TABLE 111 SOUTH KOREA: ANTICOAGULATION MARKET, BY ROA, 2017–2027 (USD MILLION) 83

TABLE 112 SOUTH KOREA: ANTICOAGULATION MARKET, BY DISTRIBUTION CHANNEL, 2017–2027 (USD MILLION) 83

TABLE 113 REST OF ASIA-PACIFIC: ANTICOAGULATION MARKET, BY DRUG CLASS, 2017–2027 (USD MILLION) 84

TABLE 114 REST OF ASIA-PACIFIC: ANTICOAGULATION MARKET, BY DIRECT ORAL ANTICOAGULANTS (DOACS), 2017–2027 (USD MILLION) 84

TABLE 115 REST OF ASIA-PACIFIC: ANTICOAGULATION MARKET, BY DISEASE INDICATION, 2017–2027 (USD MILLION) 84

TABLE 116 REST OF ASIA-PACIFIC: ANTICOAGULATION MARKET, BY ROA, 2017–2027 (USD MILLION) 85

TABLE 117 REST OF ASIA-PACIFIC: ANTICOAGULATION MARKET, BY DISTRIBUTION CHANNEL, 2017–2027 (USD MILLION) 85

TABLE 118 REST OF THE WORLD: ANTICOAGULATION MARKET, BY COUNTRY, 2017–2027 (USD MILLION) 86

TABLE 119 REST OF THE WORLD: ANTICOAGULATION MARKET SHARE, BY COUNTRY 2019 (%) 86

TABLE 120 REST OF THE WORLD: ANTICOAGULATION MARKET, BY DRUG CLASS, 2017–2027 (USD MILLION) 87

TABLE 121 REST OF THE WORLD: ANTICOAGULATION MARKET, BY DIRECT ORAL ANTICOAGULANTS (DOACS), 2017–2027 (USD MILLION) 87

TABLE 122 REST OF THE WORLD: ANTICOAGULATION MARKET, BY DISEASE INDICATION, 2017–2027 (USD MILLION) 87

TABLE 123 REST OF THE WORLD: ANTICOAGULATION MARKET, BY ROA, 2017–2027 (USD MILLION) 88

TABLE 124 REST OF THE WORLD: ANTICOAGULATION MARKET, BY DISTRIBUTION CHANNEL, 2017–2027 (USD MILLION) 88

TABLE 125 MIDDLE EAST: ANTICOAGULATION MARKET, BY DRUG CLASS, 2017–2027 (USD MILLION) 88

TABLE 126 MIDDLE EAST: ANTICOAGULATION MARKET, BY DIRECT ORAL ANTICOAGULANTS (DOACS), 2017–2027 (USD MILLION) 89

TABLE 127 MIDDLE EAST: ANTICOAGULATION MARKET, BY DISEASE INDICATION, 2017–2027 (USD MILLION) 89

TABLE 128 MIDDLE EAST: ANTICOAGULATION MARKET, BY ROA, 2017–2027 (USD MILLION) 89

TABLE 129 MIDDLE EAST: ANTICOAGULATION MARKET, BY DISTRIBUTION CHANNEL, 2017–2027 (USD MILLION) 90

TABLE 130 AFRICA: ANTICOAGULATION MARKET, BY DRUG CLASS, 2017–2027 (USD MILLION) 90

TABLE 131 AFRICA: ANTICOAGULATION MARKET, BY DIRECT ORAL ANTICOAGULANTS (DOACS), 2017–2027 (USD MILLION) 90

TABLE 132 AFRICA: ANTICOAGULATION MARKET, BY DISEASE INDICATION, 2017–2027 (USD MILLION) 91

TABLE 133 AFRICA: ANTICOAGULATION MARKET, BY ROA, 2017–2027 (USD MILLION) 91

TABLE 134 AFRICA: ANTICOAGULATION MARKET, BY DISTRIBUTION CHANNEL, 2017–2027 (USD MILLION) 91

TABLE 135 LATIN AMERICA: ANTICOAGULATION MARKET, BY DRUG CLASS, 2017–2027 (USD MILLION) 92

TABLE 136 LATIN AMERICA: ANTICOAGULATION MARKET, BY DIRECT ORAL ANTICOAGULANTS (DOACS), 2017–2027 (USD MILLION) 92

TABLE 137 LATIN AMERICA: ANTICOAGULATION MARKET, BY DISEASE INDICATION, 2017–2027 (USD MILLION) 92

TABLE 138 LATIN AMERICA: ANTICOAGULATION MARKET, BY ROA, 2017–2027 (USD MILLION) 93

TABLE 139 LATIN AMERICA: ANTICOAGULATION MARKET, BY DISTRIBUTION CHANNEL, 2017–2027 (USD MILLION) 93

TABLE 140 MAJOR MANUFACTURERS RANKING, 2019 96

TABLE 141 TOP PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE ANTICOAGULATION MARKET 97

TABLE 142 NEW PRODUCT LAUNCHES 97

TABLE 143 PFIZER, INC: PRODUCTS/SERVICES OFFERED 100

TABLE 144 SANOFI: PRODUCTS/SERVICES OFFERED 103

TABLE 145 JOHNSON & JOHNSON SERVICES INC.: PRODUCTS/SERVICES OFFERED 105

TABLE 146 JOHNSON & JOHNSON SERVICES INC: KEY DEVELOPMENTS 105

TABLE 147 GLAXOSMITH KLINE PLC: PRODUCTS/SERVICES OFFERED 107

TABLE 148 DAIICHI SANKYO COMPANY, LIMITED: PRODUCTS/SERVICES OFFERED 109

TABLE 149 DAIICHI SANKYO COMPANY, LIMITED: KEY DEVELOPMENTS 109

TABLE 150 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCTS/SERVICES OFFERED 112

TABLE 151 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: KEY DEVELOPMENTS 113

TABLE 152 BRISTOL-MYERS SQUIBB COMPANY: PRODUCTS/SERVICES OFFERED 115

TABLE 153 PORTOLA PHARMACEUTICALS, INC: PRODUCTS/SERVICES OFFERED 117

TABLE 154 PORTOLA PHARMACEUTICALS, INC: KEY DEVELOPMENTS 117

TABLE 155 NOVARTIS AG: PRODUCTS/SERVICES OFFERED 120

TABLE 156 F. HOFFMANN-LA ROCHE LTD: PRODUCTS/SERVICES OFFERED 122

LIST OF FIGURES

FIGURE 1 MARKET SYNOPSIS 14

FIGURE 2 ANTICOAGULATION MARKET STRUCTURE 15

FIGURE 3 BOTTOM-UP AND TOP-DOWN APPROACHES 21

FIGURE 4 MARKET DYNAMICS: ANTICOAGULATION MARKET 24

FIGURE 5 DRIVER IMPACT ANALYSIS 26

FIGURE 6 RESTRAINT IMPACT ANALYSIS 26

FIGURE 7 VALUE CHAIN ANALYSIS: ANTICOAGULATION MARKET 28

FIGURE 8 PORTER’S FIVE FORCES ANALYSIS: ANTICOAGULATION MARKET 30

FIGURE 9 GLOBAL ANTICOAGULATION MARKET, BY DRUG CLASS, 2019 & 2027 (USD MILLION) 35

FIGURE 10 GLOBAL: ANTICOAGULATION MARKET, USAGE, 2019 & 2027 (USD MILLION) 41

FIGURE 11 GLOBAL: ANTICOAGULATION MARKET, ROA, 2019 & 2027 (USD MILLION) 45

FIGURE 12 GLOBAL: ANTICOAGULATION MARKET, DISTRIBUTION CHANNEL, 2019 & 2027 (USD MILLION) 48

FIGURE 13 GLOBAL: ANTICOAGULATION MARKET, BY REGION 2019 & 2027 (USD MILLION) 51

FIGURE 14 GLOBAL: ANTICOAGULATION MARKET SHARE, BY REGION 2019 (%) 52

FIGURE 15 NORTH AMERICA: ANTICOAGULATION MARKET SHARE, BY COUNTRY 2019 (%) 53

FIGURE 16 EUROPE: ANTICOAGULATION MARKET SHARE, BY COUNTRY 2019 (%) 59

FIGURE 17 BENCHMARKING OF MAJOR COMPETITORS 95

FIGURE 18 SALES & OPERATING INCOME, 2019 98

FIGURE 19 R&D EXPENDITURE, 2019 98

FIGURE 20 PFIZER, INC: FINANCIAL OVERVIEW SNAPSHOT 100

FIGURE 21 PFIZER, INC: SWOT ANALYSIS 101

FIGURE 22 SANOFI: FINANCIAL OVERVIEW SNAPSHOT 102

FIGURE 23 SANOFI: SWOT ANALYSIS 103

FIGURE 24 JOHNSON & JOHNSON SERVICES INC.: FINANCIAL OVERVIEW SNAPSHOT 104

FIGURE 25 JOHNSON & JOHNSON SERVICES INC.: SWOT ANALYSIS 105

FIGURE 26 GLAXOSMITHKLINE PLC: FINANCIAL OVERVIEW SNAPSHOT 106

FIGURE 27 GLAXOSMITHKLINE PLC: SWOT ANALYSIS 107

FIGURE 28 DAIICHI SANKYO COMPANY, LIMITED: FINANCIAL OVERVIEW SNAPSHOT 108

FIGURE 29 DAIICHI SANKYO COMPANY, LIMITED: SWOT ANALYSIS 109

FIGURE 30 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: FINANCIAL OVERVIEW SNAPSHOT 112

FIGURE 31 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: SWOT ANALYSIS 113

FIGURE 32 BRISTOL-MYERS SQUIBB COMPANY: FINANCIAL OVERVIEW SNAPSHOT 114

FIGURE 33 BRISTOL-MYERS SQUIBB COMPANY: SWOT ANALYSIS 115

FIGURE 34 PORTOLA PHARMACEUTICALS, INC: FINANCIAL OVERVIEW SNAPSHOT 116

FIGURE 35 PORTOLA PHARMACEUTICALS, INC: SWOT ANALYSIS 118

FIGURE 36 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT 119

FIGURE 37 NOVARTIS AG: SWOT ANALYSIS 120

FIGURE 38 F. HOFFMANN-LA ROCHE LTD: FINANCIAL OVERVIEW SNAPSHOT 122

FIGURE 39 F. HOFFMANN-LA ROCHE LTD: SWOT ANALYSIS 123

お問合せフォーム